| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | For more information, or to get in contact with any of these companies, send an email to ZanL@israeltrade.gov.il and we'll be glad to assist with an intro | |||||||||||||||||||
2 | Company | One-liner | Description | Product Type | Tech Tags | Therapeutic areas | Company stage | Funding Round | Funding raised (USD) | Revenue (USD) | Notable customers/partners | Looking to raise (USD) | FDA approval or clearance | Est time until FDA decision | Looking to meet | Business model | US presence | Company Deck | Product Demo | |
3 | 270Surgical | First-in-class specialty laparoscopy system with 270˚ field of view | A breakthrough specialty laparoscopy system that offers a 270˚ field-of-view, which is up to a 3x improvement over the standard of care, without sacrificing image quality. The system also eliminates lens fogging and provides an enhanced visualization capability through smoke. With 270 Surgical, surgeons will be able to “see more, do more”. The system is fully compatible with any installed system in the OR, and will first target the bariatric, foregut and colorectal laparoscopy markets. It is also the first laparoscopy system for the laparoscopic trauma and cardiac surgery markets. | Medical Devices | Endoscope & Accessories | General Surgery | Regulatory Approval | Series B | $24 million | No | Agate Medical Investments, Corundum Open Innovation | $20 million | Yes | Version 1 is approved. Expect version 2 approval in ~6 months (510K) | Investors, VC's | Hardware, B2B, B2C | Dallas Texas, 1 (Chad Croasdale, President & Chief Commercialization Officer) | Link here | Link here | |
4 | AntiShock | Personalized fluid management system by continuous and non-invasive micro-hemodynamic monitoring | Intravenous fluid infusion is one of the most common interventions in medicine, and the cornerstone of treatment for a wide range of medical conditions, especially in critically ill patients including sepsis patients. Uncontrolled fluid management often leads to fluid overload which results in increased morbidity, mortality, readmission rates, medical interventions, and length of stay by 20% (LoS). Current practices mange fluids by macrohemodynamic monitoring which do not always correlate with impaired tissue perfusion called microcirculation, which is not monitored. By non-invasively, continuously, and reliable systemic tissue perfusion monitoring, AntiShock enables fluid management optimization. | Digital Health | Disease Management, Imaging, Monitoring, Remote Monitoring | Cardiovascular, General Surgery, Intensive Care, Nephrology | Seed | Pre-seed | $850K - MindUP & Atidim Fund | No | N/A | $4M | No | 4 years from now we expect to have FDA | Payers (Insurance), Investors, Hospitals, VC's, Physicians/Physician's Groups | Hardware, Fee for service, other | Offices at Israel, 3 employees | Link here | Link here | |
5 | Argaman Technologies Ltd. | Disease protection through active textiles | Developers of system for the treatment of textiles fibers which render them self-sterilizing for the (drastic) reduction of hospital acquired infections, for viral deactivation products, for fire proof products, and for cosmetic products that reduce skin wrinkles. | Medical Devices | Hospital Operational / Workforce / Financial Efficiency, Medical Equipment, Nursing Applications, Population Health Management | Diabetics, General Health, Infection Control | Regulatory Approval | 3 | $14M | $5M | German Government, US Department of Defense, US Air Force | $30M | We do not need | First product Q1 2021 | Hospitals, Physicians/Physician's Groups | B2B | None | Link here | Link here | |
6 | Binah.ai | AI-powered Video-based Health and Wellness Monitoring Solutions | Removing the need for wearables or home medical equipment, Binah.ai’s award-winning solution applies a unique mix of signal processing and AI technologies to transform any camera-equipped device (smartphone, tablet, laptop) into a vital signs monitoring tool. Just by looking at a device’s camera, users can measure heart rate, HRV, oxygen saturation, respiration rate, mental stress and soon, blood pressure. Measurements are displayed in less than 1 minute, with medical-grade accuracy. Delivered as an SDK or end-to-end application platform, it supports all ages, genders and skin colors. | Digital Health | Mobile Healthcare, Remote Monitoring, Telemedicine Solutions, Medical insurance | Emergency Medicine, General Health, Primary Care | Revenue Growth, Released | Series B | $14.5M (Maverick Ventures Israel Esplanade Ventures Sompo International GiTV iAngels) | Yes, in the millions | SOMPO Japan, Generali Deutschland,Momentun Metropolitan South Africa | $60M | In process | We expect the approval during 2021 | Providers, Payers (Insurance), Investors, Pharma, Health IT companies (EMRs), Hospitals, Distributors, VC's, Integrators, Rehabilitation Centers,Assisted Living Facilities, Physicians/Physician's Groups, Large Tech Companies (Facebook, Google, Etc.) | SaaS, B2B, | Office in Maryland, with a team of 4 employees, all sales | Link here | Link here | |
7 | BioChange | Biological scaffold stimulating tissue renewal | BioChange is a biotech startup in tissue engineering and regenerative medicine that has developed a unique injectable scaffold that stimulates guided tissue regeneration. | Medical Devices | Biomaterials & Plasma Products, Gene Therapy & Molecular Biology, Medical Equipment, Natural Materials | Dermatology & Aesthetics, Internal Medicine, Urology | Pre-Clinical | Series A | $600k and Horizon2020 grant for $50k. Investors include Mauro Wjuniski, Formerly of Alma Lasers | No | Some undisclosed but recently established R&D cooperation with University of Milan and Italian company BEL for joint research in treating COPD with our technology and their expertise and delivery systems (published on our website). | ~$7M | No | We are a medical device, finalizing pre-clinical phase so did not meet yet with the FDA, probably will have first FDA application in 2025. | Investors | other | Link here | Link here | ||
8 | BioView Ltd | Imaging and Analysis of Circulating Tumor Cells | For nearly two decades BioView has been developing, manufacturing and marketing innovative automated cell imaging and analysis solutions, for use in cytology, cytogenetic, pathology clinical and research laboratories. The most recent product offering is the DeNovo – an all-in-one scanner that incorporates cutting-edge technology, which enables highly accurate automation and standardization of CTC detection and characterization. Easy to operate and integrate with any circulating tumor assay, DeNovo greatly enhances liquid biopsies, supporting their introduction into the clinical routine. | Medical Devices | Diagnostic, Imaging, Laboratory Systems, Medical Equipment | Hematology, Oncology, Prenatal, Urology | Revenue Growth | Publicly Traded Company ( TASE) | $20M | $10M | Abbott Molecular, Sanmed Biotech, ANGLE Plc | $20M | Yes | N/A | Payers (Insurance), Investors, Hospitals, Distributors, Physicians/Physician's Groups | Saas, Hardware, Fee for service | BioView Inc. , Billerica, MA 10 employees | Link here | Link here | |
9 | Carmel Diagnostics | A ground-breaking medical system selecting the most viable embryos for successful IVF pregnancy | Carmel Diagnostics is a medtech company who developed an innovative method for measuring Oxidative Stress (OS) of a biological liquid, a recognized biomarker of health and disease and a key diagnostics parameter. This OS parameter is measured by TCL (ThermoChemiLuminescence), an advanced yet simple technology. Carmel’s lead product is Embryo Selection in IVF process. Carmel won the prestigious Phase-2 grant from Horizon2020, planning market launch by Q1/2021. It has an experienced, motivated team. | Medical Devices | Biomarkers, Biosensors & Glycolic, Diagnostic Kits, Medical Equipment, Point of Care Diagnostics | Gynecology, Infertility, Inflammation | Regulatory Approval | Series A | $7M - private investors and grants | No | IVI VALENCIA | $4M | No | 1 year | Investors, Integrators, Other | B2B | No | Link here | Link here | |
10 | Clew Medical | Critical Care Enhanced by Al-powered predictive analytics | Using machine learning and data science, CLEW has developed physiological, predictive models at the individual patient level. Already proven successful in the ICU, the models are now being extended to all care settings, designed to guide healthcare providers in predicting the patient’s clinical state. Deployable directly from bedside to a centralized command and control facility, CLEW helps providers make better informed clinical decisions; improve outcomes and safety; streamline patient care; better deal with increased regulation and penalties; lower the cost of care; and remove discharge barriers. | Digital Health | Artificial Intelligence, Decision Support System, Precision / Personalized Medicine | Cardiovascular, Intensive Care, Primary Care | Released | Series C | $22M | $0.5M | Umass , WakeMed , Sheba | $20M | Yes | Have an EUA , in few weeks 510K | Providers, Payers (Insurance), Investors, Hospitals, VC's, Integrators | Saas | Yes, virtual office, 3 employees | Link here | Link here | |
11 | DDE MRI Solutions | Breast Cancer detection in MRI procedure, without use of contrast agent | DDE MRI Solutions has developed a technological platform that eliminates the use of contrast agents (gadolinium, GBS, etc.) from MRI exams, designed to detect breast (BIT-Motion) and prostate (PIT-Motion) cancer. The patented platform consists of MRI set-up protocol and proprietary image analysis software. The platform requires no hardware and can be used with almost all existing MRI machines. | Digital Health | Artificial Intelligence, Diagnostic, Imaging | Oncology, Women's Health | Beta | 1st | $1M - Founders and Israeli Innovation Authority | No | UHN Toronto; Northshore University HealthSystem Chicago | $3M-$6M | No | We are scheduled to submit FDA during December and receive FDA clearance by April 2021 | Payers (Insurance), Investors, Hospitals, VC's | Saas | Not yet | Link here | Link here | |
12 | Donisi Health | Changing Lives Without Changing Technology | Donisi developed the only clinically validated contact-free device that can identify pulmonary congestion & more. Based on deep deck and backed by 26 registered patents, Donisi’s unique AI & proprietary algorithms enable early detection of changes in health status through on-going measurement and trend analysis of (9) cardiopulmonary parameters. | Digital Health | Artificial Intelligence, Disease Management, Remote Monitoring, Telemedicine Solutions | Cardiovascular, Respiratory | Beta | Series B | $27M: Lenovo, Chartered, Olive Tree | No | 3 care providers in the US; one fortune 500 technology company | $15M | No | FDA approval expected April 2021. | Investors, VC's, Rehabilitation Centers, Assisted Living Facilities | B2B2C, Fee for service | Yes! We have a small team in the US, located in California | Link here | Link here | |
13 | EchoCare Technologies | Comprehensive Non-Privacy Invasive and Non-Wearable Elderly Care Home system for emergency detection and preventive care | EchoCare develops a non-wearable & non-privacy invasive Elderly Care Home Observer (ECHO) system, that detects various emergencies and a potential health deterioration. In the current COVID19 period, the ECHO system becomes very essential as it can continuously monitor the respiration profile of quarantined seniors and COVID19 patients. The EchoCare’s solution consists of the installed ECHO device and the cloud service that enables the transfer of the alerts and other vital data to the remote caregiver using a web based nursing call system (dashboard). | Digital Health | Artificial Intelligence, Decision Support System, Remote Monitoring, Wearables & IOT | Intensive Care, General Health, Respiratory | Beta | Series A | ~$3M - Centrica(UK), SMK (JP), Lifeview (AU), Tigbur (IL), Incubit Ventures (IL), IIA | Yes (Initial) | Customer: LifeView Residential Care (AU) Other customers are confidential | $3M-$5M | No | 2021 for a new feature | Investors, Distributors, VC's | Hardware, B2B, B2B2C | No | N/A | Link here | |
14 | Eleos Health | The First Care Intelligence System For Behavioral Health | Eleos Health is an AI-powered workflow solution which empowers behavioral health providers to focus on care personalization, and not on data collection. We are using therapy-specific voice-analysis to surface actionable clinical insights that drive treatment outcomes straight from the session and automatically generate progress notes to enable clinicians to see more clients every day, all without changing existing clinical workflows. | Digital Health | Artificial Intelligence, Decision Support System, Hospital Operational / Workforce / Financial Efficiency, Population Health Management | General Health, Psychiatry | Initial Revenues | Seed | Lool ventures, $1.95M | Yes, <$1M | UHS | N/A | We do not need | N/A | Providers, Payers (Insurance), Investors, Health IT companies (EMRs), Hospitals, VC's, Integrators, Large Tech Companies (Facebook, Google, Etc.) | Saas, B2B | Co-Founder + 5 employees. Based in Boston. | Link here | Link here | |
15 | Emedgene | Emedgene provides a cognitive genomics intelligence platform for diagnostics and discovery at scale | Emedgene empowers health organizations to deliver precision medicine programs by providing an AI-platform for high throughput genomics diagnostics & discovery. With the reduction in sequencing prices there's an unsustainable shortage in genomic data scientists. Emedgene is on a mission to unlock genomic insights by providing data-driven solutions for diagnostics, discovery & care. Our platform helps top brands such as Mayo Clinic & Boston Children's to scale genomic programs | Digital Health | Artificial Intelligence, Bioinformatics, Drug Discovery, Genomics &Proteomics, Decision Support System, Precision / Personalized Medicine | Genetic Disorders | Revenue Growth | Series A | $10 Million (Olive Tree Ventures, Mindset Ventures) | Yes, not disclosed ($1-$10 million) | Customers: Baylor College of Medicine, Baylor Genetics, Boston Children’s, Clalit (Israel), Columbia University, Greenwood Genetic center, GrupoFleury (Brazil), Mayo Clinic, Massachusetts General Hospital, Medical College Wisconsin, NIM genetics (Spain), Undiagnosed Diseases Network, University of Miami, University of Pittsburgh Medical Center , Vanderbilt School of Medicine | $10-15 million | We do not need | NA | Providers, Payers (Insurance), Investors, Pharma, Health IT companies (EMRs), Hospitals, Distributors, VC's | Saas, B2B | 5 employees in remote offices in US & Canada | Link here | Link here | |
16 | Emerge - Medical data Intelligence | Medical population management and analytics | Our mission at Emerge is to enable healthcare providers, clinic administrators, and health networks to achieve goals that enhance, rather than impairs, the clinical relationship between caregiver and patient by normalizing data from a variety of sources and interfaces into a synthetic patient view, leveraging our Intelligence search options and modern sophisticated visualizations. | Digital Health | Clinical Document Management, EHR, Electronic Medical Records, Mobile Healthcare | Allergy, Autoimmune Diseases, Bone Diseases, General Health | Revenue Growth | N/A | NA | Yes, not disclosed | 100 clinics | NA | We do not need | NA | Health IT companies (EMRs), Integrators | B2B | Yes, 10 employees | Link here | Link here | |
17 | EyeControl | Communication device for home and ICU ventilated patients | The EyeControl is the first wearable, screenless, assistive communication device. AI-powered eye-tracking technology enables two-way remote communication between ventilated / Locked-in patients, their families and medical care teams via the hospital nurse station. The EyeControl is CE marked, FDA listed, ISO certified, AMAR registered; and is included in the Israeli “Health Basket” and the UK NHS Supply Chain. In the US, the EyeControl device was granted Medicare/Medicaid reimbursement codes. The COVID-19 pandemic intensified pre-existing needs and introduced new challenges in caring for ventilated ICU patients, including safeguarding medical staff, providing communication channels with caregivers and loved ones, and decreasing ICU Delirium rates. EyeControl empowers medical systems to effectively deal with these challenges, by providing a safe, remote communication solution that facilitates ongoing medical evaluation and contributes to Delirium prevention. The system also collects unique eye movement imaging, which is likely to become an important new data modality for non-verbal patients. | Medical Devices | Artificial Intelligence, Assistive Technologies, Monitoring, Wearables & IOT | Intensive Care, Ophthalmology, Rehabilitation, Respiratory | Initial Revenues | Series A | $15M | Yes, hundreds of thousands | NHS, Israeli Health Basket. | Not actively fundraising | Yes | Approved | Investors, Health IT companies (EMRs), Hospitals, VC's, Rehabilitation Centers, Assisted Living Facilities, Large Tech Companies (Facebook, Google, Etc.) | B2B, B2B2C, B2C | US subsidiary exists. A local office will be opened during Q12021 | Link here | Link here | |
18 | FEMSelect Ltd. | Minimally invasive approach to prolapse repair with FDA clearance and CE Mark | FEMSelect is a women-led company with a passion to make a lasting impact on women’s health by delivering innovative technologies that provide consistent results in a patient-centric manner and dramatically improve outcomes for women. Headquartered in Israel, FEMSelect developed EnPlace – a minimally invasive, mesh-free approach to prolapse repair that has FDA clearance and CE Mark. EnPlace was first used clinically over 4 years ago and has 1-year data from a 60-patient Post-Marketing Study. EnPlace has US sales and is approved at 15 US hospitals and has recently been approved in Israel’s largest Sick Fund, Clalit. | Medical Devices | Disposable & Implantable, Implantable, Minimally Invasive System | General Surgery, Gynecology, Urology, Women's Health | Initial Revenues | Series B | $8M including Israel Innovation Authority, Triventures and RAD BioMed of Israel, TransPacific and ForMed of Taiwan, | $0.3M | initial revenues in 2020--15 US hospitals including Mount Sinai in NY and Clalit Sick Fund and Assuta Hospital in Israel | $15-20M | Yes | Achieved in 2016 and then began a Post-Marketing Study | Providers, Payers (Insurance), Investors, Hospitals, VC's, Physicians/Physician's Groups | B2B, B2C | Yes, US subsidiary with 2 employees as well as co-promote agreement with LiNA Medical USA (large Danish minimally invasive gynecology company) | Link here | Link here | |
19 | Fize Medical | New Frontier in Patient Monitoring | FIZE® Medical revolutionizes the care of patients with indwelling Foley catheters by providing real-time analysis and output measurement to support informed clinical decisions in acute care. FIZE’s management and data acquisition platform enables timely intervention to improve patient’s outcomes while decreasing costs and reducing nursing time. | Medical Devices | Monitoring, Point of Care Diagnostics, Precision / Personalized Medicine, Remote Monitoring | Intensive Care, Internal Medicine, Nephrology, Urology | Beta | Series A | Rapha Capital | No | Shaare Zedek Medical Center | $3M out of total of $5M | No | N/A | Investors, Hospitals, Distributors | B2B | No | Link here | Link here | |
20 | Foresee Genomics | End to end solution for genomic diagnostics | Foresee Genomics develops a combined system of molecular biology and bioinformatics. An enabling-technology with the purpose to increase the accuracy of the currently error-prone nanopore-based DNA sequencing technology, transforming it into a technology that would be suitable for sensitive diagnostics. An end-to-end solution for genomic diagnostics which is accurate and affordable. | Biotechnology | Bioinformatics, Drug Discovery, Genomics &Proteomics, Diagnostic, Diagnostic Kits, Point of Care Diagnostics | Genetic Disorders, Hematology, Oncology | Seed | Seed | $800K from the IIA | No | MindUP | $3M | Yes | 2-5 month | Investors, VC's | Saas, Hardware, B2B | No | Link here | Link here | |
21 | Genetika+ | Truly personalised treatment for Major Depression. | Genetika+ is developing a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. The test uses innovative technology to test all 70 + antidepressants and combinations to predict the best drug for each patient brining patients to their best treatment outcomes, faster, more effectively and with fewer side effects. | Biotechnology | Biomarkers, Biosensors & Glycolic, Decision Support System, Diagnostic, Precision / Personalized Medicine | Neuroscience, Psychiatry | Pre-Clinical | Series A | $2.6M, Howard Morgan, IIA, Meron Capital | No | Sheba Medical Center - Israel, Jefferson Medical Center - PA, USA | $10M | We do not need | NA | Payers (Insurance), Investors, VC's, Physicians/Physician's Groups | B2B2C | NA | Link here | Link here | |
22 | HelpAround | We simplify the specialty patient’s experience | HelpAround’s mission is to make patients’ lives easier. Founded by health-tech and behavioral targeting experts, the company enables pharmaceutical brands to preempt therapy drop-off by establishing an omni-channel mobile relationship with patients and caregivers. By leveraging the platform’s unmatched connectivity across the specialty ecosystem, brand teams can transform their patient support programs into a mobile concierge experience with best-in-class mobile experience and messaging intelligence. | Digital Health | Disease Management, Medication Adherence, Mobile Healthcare, Proactive wellness / Lifestyle / Patient Engagement | Oncology, Neurology & Degenerative Disease, Cardiovascular, Dermatology & Aesthetics | Initial Revenues | Series A | $6M - Investors: IQVIA, ConnectiveRx, Windham Ventures, Winshall (PillPack investors) | $1M | Chiesi, Morphosys | $2M | NA | NA | Pharma, Health IT companies (EMRs) | SaaS, B2B | Yes, 4 employees (Sales and Marketing) | Link here | Link here | |
23 | IDenta Ltd | Drug Testing Kits | IDenta is a global leader in the development and supply of Field Detection and Home Diagnostics Testing Kits for Drugs & Explosives and Unique Forensic Products in the Homeland Security and Consumer Markets. IDenta develops, manufactures and distributes revolutionary products for both the professional Law and Retail markets which consistently pass the highest qualifications and testing procedures of law enforcement and security agencies around the world. | Medical Devices | Chemicals, Biological and others, Diagnostic Kits, Tools | General Health, Rehabilitation | Revenue Growth | 4 | $4M - angels | $0.5M | Government Agencies. Retailers. | $3M | We do not need | Test is external | Investors, Pharma, Distributors, VC's, Rehabilitation Centers | B2B, B2B2C, B2C | HQ in Israel. One office in US. | Link here | Link here | |
24 | IMedis | AI driven quality management platform for radiology departments | IMedis is an Israel-based digital health company backed by Sanara Ventures, aimed at developing a first-in-kind quality-management platform for radiology departments. The platform, uses a novel and patent pending combination of image and text analysis using AI, allowing to correlate between early-stage cancer and cardiovascular signs in CT scans to the interpretation in the radiology report, and alert radiologists to overlooked actionable findings. IMedis is now in search of SAFE note investment of $2M as part of an $8M A round planned to be finalized by end of 2021. | Digital Health | Artificial Intelligence, Decision Support System, Diagnostic, Imaging | Cardiovascular, General Health, Oncology | Regulatory Approval | Series A | $2.25M, Sanara Ventures, CBG, GRG, IIA | No | UCSD, TASMC | $8M | No | 10-12 months | Providers, Investors, Health IT companies (EMRs), Hospitals, VC's | Saas, B2B | None yet | Link here | Link here | |
25 | IMNA Solutions | A data‐driven approaches using PGHD to identify and intervene early on in clinically significant events. | Remote patient monitoring alone is no longer sufficient. To cut through this noise, IMNA has developed breakthrough technology that identifies the data that is most clinically relevant and delivers actionable insights to help providers tailor their care and optimize treatment outcomes. The IMNA platform delivers 3 critical areas of functionality that assess each patient’s physical and mental state, along with adherence to treatment protocols critical to achieving desired outcomes. We call this Personalized Patient Pathway (P3) | Digital Health | Decision Support System, Metadata & Research Tools, Remote Monitoring, Telemedicine Solutions | Cardiovascular, Diabetics, Obesity, Oncology | Initial Revenues | Seed | $6M | $0.25M | Elad Health, Novo Nordisk, Garmin Health, Shiba Medical Center, Rambam Hospital | $3.5M | We do not need | n/a | Providers, Investors, Pharma, Hospitals, Distributors, VC's, Physicians/Physician's Groups, Large Tech Companies (Facebook, Google, Etc.), Other | Saas, B2B, B2B2C, other | 3 employees Arizona | Link here | Link here | |
26 | Kencap | Single use instruments and home care devices | Kencap Medical Solutions are an established and well-known name in the healthcare industry. We are manufacturers of single use instruments for the healthcare industry, and also the inventors of the Eardoc. We design and manufacture all our instruments in-house. We do not copy or imitate instruments – we design them ourselves so we can improve the available instruments – and make them better. We have vast knowledge in product design, production and go-to-market of devices and instruments. | Medical Devices | Disposable & Implantable, Distributors, Hospital Units/Clinics | Gynecology, Inflammation, Women's Health | Revenue Growth | Yes | Amir Porat | $1M | can't show | $2M | Yes | Have FDA | Hospitals, Distributors | B2B | No | Link here | Link here | |
27 | Koalys | Digital, web & cloud based hearing care, including tele-audiology | Koalys is a comprehensive SaaS platform for Audiology. We provide the means to perform hearing tests for screening, diagnostic and fitting. Our turnkey solutions are designed for both audiology professionals and people without any audiological background. Koalys leverages the latest technological developments to introduce solutions that are cloud based, digital and mobile. We use AI, Machine Learning and Big Data to provide cost effective and more accurate hearing care to anyone anywhere. Koalys is CE marked, FDA registered, ISO compliant, GDPR and HIPAA compliant. | Digital Health | Diagnostic, Point of Care Diagnostics, Telemedicine Solutions | Ear, Nose and Throat (ENT), General Health, Pediatrics, Primary Care | Initial Revenues | Series A | Owner's out of pocket money | $0.5M | Acuitis, Audition Benoit, Grand Audition, Optical Center | $3-5M | Yes | Already have FDA | Providers, Payers (Insurance), Investors, Hospitals, Distributors, VC's, Physicians/Physician's Groups | Saas, B2B | Not yet | Link here | Link here | |
28 | Leviticus Cardio | Wireless LVAD - quality of life for heart-failure patients | Leviticus Cardio’s wireless power transfer technology, Coplanar Energy Transfer, combined with an existing Ventricular Assist LVAD system, provides a new, robust, comprehensive hybrid solution for CHF patients. Leviticus FiVAD™ is wirelessly charged using an external belt along with an internal battery that lasts 6-8 hours. Patients may expect an improved Quality of Life with Leviticus FiVAD™ because they are free from external equipment for many hours per day. | Medical Devices | Assistive Technologies, Implantable, Medical Equipment | Cardiovascular | Clinical Trials | Series B | $12M - BHBV, Trendlines, IIA | No | Jarvik Heart | $10M | No | We in process - 8 month to start EFS 2 year for approval | Investors, VC's | B2B, B2C | N/A | Link here | Link here | |
29 | LuSeed - Vascular | LuSeed provides a new degree of freedom for treating vasculature, by enabling to thicken the wall of a blood vessel up to full closure. | LuSeed provides a new degree of freedom for treating vasculature, by enabling to thicken the wall of a blood vessel up to full closure. LuSeed utilizes a proprietary tissue enhancing technology, using electromagnetic wave emission, designed for controlled vascular remodeling & Robust tissue growth. This innovative tech platform's first application is designed for cerebral aneurysms and could be applied for Heart valves & Aortic aneurisms as well. | Medical Devices | Disposable & Implantable, Implantable, Minimally Invasive System | Cardiovascular, Neurology & Degenerative Disease, Neuroscience, Peripheral Vascular | Pre-Clinical | Series A | $1.55M | No | Research is done along with an MIT facility, a KOL in the neurovascular field is a highly involved | $6M | No | Around 5 years | Investors, VC's, Integrators, Physicians/Physician's Groups, Other | B2B | No current US presence | Link here | Link here | |
30 | Lyra Medical | A proven, safer, implantable solution for Pelvic Organ Prolapse treatment | Lyra Medical has developed a new implant for the treatment of pelvic organ prolapse (POP). The patented Self-Retaining Support (SRS) technology eliminates the need for complex anchoring techniques to assure a safe, easy to use and long-term treatment solution. The anchorless solution mimics the physiologic support, restoring pelvic organs to their anatomical location. The SRS Implant is the only product that has delivered exceptional safety and long-term efficacy through clinical trials prior to being approved for general use. The SRS Implant is currently available for use in Europe and Israel. | Medical Devices | Implantable, Minimally Invasive System | Gynecology, Urology, Women's Health | Initial Revenues | 4th | $4.1M from angels | $350K (2019), ~$500K (2020 (Covid-19 year)) | pfm-medical, a German company. Among their large products portfolio, they developed and sale urogyn implants. They decided to replace their transvaginal mesh implant with Lyra's SRS Implant, and distribute our SRS Implant to their customers in number of EU countries. Also Clalit - Israeli biggest HMO and Assuta - Israeli biggest privet hospitals chain | $16M | No | Main use of proceed is planed for FDA approval. We assume 3-4 years process | Investors, Distributors, VC's | B2B | None as of yet. We intend to open US operations once completing this fundraising round | Link here | Link here | |
31 | Maverick Medical AI | Transforming Medical Coding for Payers and Providers with Deep Learning AI | We are an early commercial-stage company with locations in Israel and the US offering the first commercially trained deep learning neural network based on big data of real sub-specialized clinical data. Our Clinical AI Cognition™ Platform understands and converts the unstructured text of patient reports to valuable medical codes, providing a single platform automating the medical coding process for payers and providers across all care settings. Healthcare payers and providers are overwhelmed with patient data. An increase in coding efficiency, capacity, and accuracy has the highest impact on their revenue. | Digital Health | Artificial Intelligence, Electronic Medical Records, Hospital Operational / Workforce / Financial Efficiency, Medical insurance | General Health | Revenue Growth | Series A | $1.4M The Time Technologic Incubator, L.P. Firstime Ventures II, L.P. | $0.48M | Mount Sinai Hospital, NY | $12M | We do not need | N/A | Providers, Payers (Insurance), Investors, Health IT companies (EMRs), Hospitals, VC's, Physicians/Physician's Groups, Large Tech Companies (Facebook, Google, Etc.) | Saas, B2B | 1 employee 6519 Arbor Point, Flowery Branch GA 30542 | Link here | Link here | |
32 | Medispec | Global leader in Innovative non-invasive ShockWave Technologies | With nearly 30 years of experience in innovative non-invasive therapies, such as shockwave technologies, Medispec is introducing world leading solutions for the Urology, Cardiovascular, Orthopedic and Sexual medicine domains. Medispec non-invasive solutions are leading worldwide with its robust clinical trials activities, which continuously proves Medispec's solutions safety and effectiveness. | Medical Devices | Imaging, Medical Equipment | Cardiovascular, Nephrology, Orthopedic, Urology | Revenue Growth | 1st | No external Investment was made in the Company since its establishment | $10M | Private company, Not available for public | $10M | Yes | We have FDA for some products. 2-3 years if we want to submit FDA for our new Project for kidney failure repair | Investors, Hospitals, Distributors | Saas, B2B, B2C | Yes, USA fully owned subsidiary in Maryland USA | Link here | Link here | |
33 | Medorion | A member-intelligence SaaS solution for Health Plans | Medorion's member-intelligence SaaS solution uses claims and demographic data to help healthcare organizations understand why people behave the way they do and then translate these insights into highly targeted communication plans. It is similar technology to what companies like Netflix/Amazon/Spotify use to hone in on their customer needs - we can do this with healthcare data. To date, our platform manages 470k members from a handful of U.S. health plans and across 11 objectives (From drug adherence through cancer screening and up to M.A. member retention and acquisition). We're on a $1.5m ARR. | Digital Health | Artificial Intelligence, Web/Internet Solutions | General Health | Initial Revenues | Series A | $2.8m. iAngels, TAU Ventures | $1.8M | Blue Cross Blue Shield of Michigan | $7M | We do not need | NA | Payers (Insurance), Investors, VC's, Large Tech Companies (Facebook, Google, Etc.) | Saas, B2B | One employee and growing | Link here | Link here | |
34 | MindUP | Israel's Digital Health Incubator | MindUP is a JV of Medtronic, IBM, Pitango VC and Rambam Medical Center in collaboration with the Israel Innovation Authority. MindUP funds, supports and nurtures early stage digital health projects. MindUP translates disruptive technologies and promotes new companies into leading digital health ventures, that will create cutting edge technologies and products. | Digital Health | Artificial Intelligence, Decision Support System, Diagnostic, Monitoring | Cardiovascular, General Health, Intensive Care, Women's Health | N/A | N/A | N/A | N/A | Medtronic, IBM, Pitango VC, Rambam Medical Center | N/A | We do not need | N/A | Providers, Payers (Insurance), Investors, VC's, Rehabilitation Centers, Assisted Living Facilities | other | No | Link here | Link here | |
35 | Montfort Brain Monitor | Smartphone-based, FDA-cleared, remote patient monitoring for neurological conditions | Montfort offers enterprises (hospitals, medical device manufacturers, pharma industry) SaaS, allowing tests at the clinic and home, both of which are reimbursable with exiting CPT codes. Among our clients are Medtronic and Teva Pharmaceuticals Industries. An App is running standard neurological tests by using a standard smartphone, thus allowing virtual neurological examination to be conducted anytime, anywhere. Our proprietary algorithms and AI, translate the data captured by those sensors into actionable insight, used for diagnostics, treatment personalization and clinical trials. | Digital Health | Artificial Intelligence, Diagnostic, Remote Monitoring, Telemedicine Solutions | Nephrology, Orthopedic, Psychiatry | Initial Revenues | Series A | $1.3M from Next Leap Ventures and IIA grants | $0.2M | Medtronic, Henry Ford Health Systems, Charitte, Queen Mary hospital | $4M | Yes | We have FDA clearance | Providers, Investors, Hospitals, Distributors, VC's, Large Tech Companies (Facebook, Google, Etc.) | Saas | None | Link here | Link here | |
36 | NanoScent | Chemical sensors capable of detecting unique volatile organic compounds signature of viral infection | NanoScent was founded in 2017 to develop a scent recognition technology, capable of improving safety and personal wellbeing, in addition to providing environmental protection and energy efficiency. The patented NanoScent technology is based on proprietary nanosensors, coupled with machine learning algorithms that identify specific signatures within mixtures of volatile organic compounds (VOCs) in air samples, which derive from the immune or microbiome response to an infection. Scent Check™ will enable testing in controlled settings where visitors are screened prior to access, such as schools, airports, hospitals, and large gatherings | Biotechnology | Artificial Intelligence, Biomarkers, Biosensors & Glycolic, Decision Support System, Mobile Healthcare | General Health, Infection Control, Infectious Diseases, Metabolic Diseases | Pre-Clinical | Series A | $9M - Sumitomo Chemicals, Dreamtech, European Investment Bank | $3M | Sumitomo Chemicals, Dreamtech, Toto | $20M | No | We are awaiting EUA process | Providers, Investors, Health IT companies (EMRs), Distributors, Large Tech Companies (Facebook, Google, Etc.) | B2B, B2B2C | Not yet, 34 employees in Israel | Link here | Link here | |
37 | Nanosynex | Rapid diagnostic platform for testing bacterial resistance to antibiotics. | Nanosynex is an Israeli medtech startup focused on the urgent need of rapid diagnostics tests for bacterial susceptibility and resistance to antibiotics. Perfect example of bioconvergence, Nanosynex rapid and accurate solution is composed of disposable microfluidic cards, a benchtop reader and a data collection software. The test allows doctors to determine the appropriate antibiotic treatment for their patients and provide same-day-results, therefore saving lives, reducing the spread of resistant bacteria and cutting healthcare costs. The company's scientific basis comes from the lab of Professor Shulamit Levenberg, Dean of the Technion Biomedical Engineering Faculty. Nanosynex team is composed of passionate, dedicated business executives, top-notch multidisciplinary engineers and supported by a network of experts, including strategic alliances with future distributors. | Medical Devices | Diagnostic, Laboratories, Microbiology, Point of Care Diagnostics | Infectious Control, Infectious Diseases, Urology | R&D | Series A | $5.8M to date, including $4.8M in non-dilutive funding | No | NA | $8M | No | 3-5 years | Payers (Insurance), Investors, Hospitals, VC's | B2B | 1 employee (San Diego) | Link here | Link here | |
38 | NeuroAudit | Personal patch device. driving an instant cognitive boost for focus effect | NeuroAudit is a multidisciplinary startup based since 2016 and developing an innovative Psychoacoustics neurostimulation technology steered for personalized treatment of brain disorders. NeuroAudit has developed the first disposable neuro stim patch for daily use driving an instant cognitive boost. NeuroAudit tackles the complexity of neurological disorders by continuous monitoring of the brain state and data-driven effective neurostimulation. Our vision is to develop closed-loop AI powered monitoring-stimulation cycles that targets the specific user, tracking and adapting throughout the Treatment course. NeuroAudit is currently conducting a monitoring study under unique stimulation to improve an instant cognitive boost toward treating Alzheimer diseases as a first step. | Medical Devices | Artificial Intelligence, Drug Delivery, Medical Equipment, Personal Health Assistant | Neuroscience | Seed | Seed | $0.2M | No | N/A | $4.2M | We do not need | N/A | Investors, Hospitals, VC's | B2B | N/a | Link here | Link here | |
39 | NewStem | Software predicting patient’s likelihood of being resistant to anti-cancer drugs | NewStem Ltd. is a biotechnology company possesses pioneering intellectual property of Haploid Human Embryonic Stem Cells - HhPSCs and robust genome-wide genetic screening. These technologies are utilized for the development of AI-based personalized diagnostics for early detection of anti-cancer drug resistance as well as revealing new therapeutic targets for cancer. The company’s most progressed product under development is in the field of precision oncology; Identifying resistance to the drug prior to commencing anti-cancer treatment. | Digital Health | Bioinformatics, Drug Discovery, Genomics &Proteomics, Decision Support System, Diagnostic, Precision / Personalized Medicine | Genetic Disorders, Oncology | R&D | Series A | $4M NovelStem international Corp | No | n/a | $10M | No | Pre-Submission was sent, full submission expected H12020 | Providers, Investors, Pharma, Hospitals, VC's, Other | B2B2C | Active Investors; NovelStem International Corp | Link here | Link here | |
40 | NINA Medical | Treatment without trauma - non invasive image guided treatment for BPH | The idea emerged on the soccer playground in Tel-Aviv, where three friends (and ultrasound experts) used to meet for the weekly match. It was: can we 'see' the HIFU (high intensity focused ultrasound) with imaging ultrasound? After many fouls and goals, NINA Medical was established in 2019, by Shmuel Ben-Ezra and Yoni Hertzberg, with Alex Volovick as an advisor. The company aims to introduce image-guided non-invasive surgery, with HIFU energy for the therapeutic part, and diagnostic ultrasound for imaging. Yes – this is the basis for the company’s IP. | Medical Devices | Imaging, Minimally Invasive System | Neurology & Degenerative Disease, Urology | Proof of Concept | Series A | $0.9M USD (NIS 3M) from Israel Innovation Authority and NGT3VC | No | NA | $5M | No | NA | Payers (Insurance), Investors, Distributors, VC's, Large Tech Companies (Facebook, Google, Etc.) | Hardware, Fee for service | NA | Link here | Link here | |
41 | NovaSight | Eye tracking based vision care solutions | NovaSight is an Israeli start-up that focuses on bringing pediatric vision care into the digital age using advanced eye tracking technology. NovaSight offers two flagship products: The CureSight™ system is an eye-tracking based lazy eye treatment intended to replace traditional eye patching. It is designed to provide cloud monitoring to caregivers and physicians while the child watches their content of choice from the comfort of home. The EyeSwift® system is a comprehensive portable vision assessment device which accurately and objectively screens for multiple vision impairments within seconds. future pipeline product include automatic detection and monitoring of retinal diseases and cognitive disfunctions such as Dyslexia and ADHD and innovative eye tracking based active glasses for myopia control. | Digital Health | Diagnostic, Medical Equipment, Telemedicine Solutions | Ophthalmology, Pediatrics | Clinical Trials | Series B | $16M. Rimonci strategic investor both from Medical and Pharma | $0.5M | Essilor | $10-15M | Yes | 12 months | Providers, Payers (Insurance), Investors, Pharma, Hospitals, Distributors, VC's, Large Tech Companies (Facebook, Google, Etc.) | Saas, B2B, B2B2C | not yet | Link here | Link here | |
42 | O2Cure Ltd. | First ever long-term blood oxygenators using novel nano-technology | Artificial lung is no longer a dream, it’s our plan. O2Cure is an Israeli-based company that develops the first ever long-term blood oxygenators and respiratory assist devices using novel carbon nanotube technology and unique design that enable efficient blood oxygenation with reduced harmful effect on blood in pumpless setup. The technology is the basis for wide range of respiratory assist devices (e.g. for COPD patients) bridge to lung transplant and up to implanted artificial lung, addressing unmet needs in a huge market with no breakthrough in the last 50 years. | Medical Devices | Medical Equipment | Pulmonary | Pre-Clinical | Series B | $6.5M, European and U.S family offices | No | None | $6M | No | 2-3 years | Investors, VC's, Large Tech Companies (Facebook, Google, Etc.) | B2B2C | None | Link here | Link here | |
43 | Owlytics Healthcare Ltd | Senior and neurology patient risk-management analytics | Owlytics's personal, wearable-based, on-line Analytics system is aimed at providing individuals with safety, independence and better health. Designed to continuously and automatically detect falls, assess fall risk and provide early warning of potential health deterioration, including sleep, night wake-ups and activity analysis, it delivers actionable outcomes that help provide better personal care while reducing healthcare costs. Differentiation- personal predictive profiling based on continuous physiology and motion signals fusion and new medical models validation accelerated modus operandi (3 months) under computerized lab at Tel-Aviv Hospital.The service is targeted on the US remote patient monitoring market: $15B/ y senior-living and home care chains and $3B/ y Neurology patients monitoring during clinical studies and home services. All remote: Owlytics monitors and protects users anywhere with no infrastructure needed by wearing a cellular enabled Samsung Active 2 smart watch and other off-the-shelf wearables. The installation, training and service are managed remotely as well. | Digital Health | Artificial Intelligence, Disease Management, Personal Health Assistant, Remote Monitoring | General Health, Neurology & Degenerative Disease, Rehabilitation | Initial Revenues | Series B | $6M - Halma CVC, CBG, Mike Berman | Yes, not disclosed | Tanabe- Neuroderm, Fellowship, St. Mark, Israeli Healthcare Ministry, TLV Hospital, Halma- Centrak | $10M | Yes | 2 years for Neurology SW- 510k | Providers, Payers (Insurance), Investors, Pharma, Distributors, VC's, Rehabilitation Centers, Assisted Living Facilities, Large Tech Companies (Facebook, Google, Etc.) | Saas, B2B, B2B2C | Boston MA office, 2 employees | Link here | Link here | |
44 | Oxitone Medical | Oxitone is a medtech and digital health company delivering AI-powered, integrated continuous monitoring solutions | Oxitone is a leading medtech and digital health company helping health care providers generate and utilize the millions of integrated continuous medical data points into effective, hyper-personalized, AI-aided therapeutic interventions. The core of the Oxitone's integrated solution is an exceptionally accurate personalized data analytics engine VitalsTone™ integrated with the #1 in the market FDA/CE certified wrist medical monitor Oxitone 1000M. | Medical Devices | Artificial Intelligence, Medical Equipment, Remote Monitoring, Wearables & IOT | Cardiovascular, Pulmonary, Rehabilitation, Respiratory | Initial Revenues | Series A+ | $10M USD. Notable Investor - Telcom Ventures | $0.3M | Cigna, Ascom, London Sleep Center, HMO Clalit | $5M | Yes | We already have FDA | Providers, Payers (Insurance), Investors, Pharma, VC's, Integrators, Rehabilitation Centers, Assisted Living Facilities, Physicians/Physician's Groups, Large Tech Companies (Facebook, Google, Etc.) | Saas, Hardware, B2B, B2B2C | US Office: Upward Hartford, 20 Church Str., Mezzanine, Hartford CT 06103, USA | Link here | Link here | |
45 | PathKeeper Surgical | 3D navigation system with real-time tracking sub-mm accuracy for spinal surgeries | PathKeeper Surgical is a medical device company utilizing AI and 3D imaging to create a paradigm shift in spinal surgeries. At present, there are millions of spinal surgeries taking place annually worldwide, with a failure rate of 20%-30%. This is due to the lack of real-time imaging and navigation assistance throughout surgery. PathKeeper has developed the first Machine-Vision Image Guided Surgery system that allows spine surgeons to perform fast, cost-effective, radiation-free spinal navigation. This ensures accurate surgical outcomes for all and decreases the need for repeat surgeries. | Medical Devices | Artificial Intelligence, Imaging, Minimally Invasive System, Robotics | Bone Diseases, Orthopedic, Pediatrics | Clinical Trials | Series A | 2.5 million Euro - Horizon 2020 grant, 1.6 million USD - angel investors and spinal surgeons | No | Top spinal surgeons worldwide on our clinical advisory board, collaboration with Hadassah Hospital in Jerusalem | $5M | No | Q3 2021 | Investors, Hospitals, Distributors, VC's, Physicians/Physician's Groups | Hardware, B2B | We have top US spinal surgeons on our clinical advisory board including Dr. Tushar Patel and Dr. Alex Vaccaro | Link here | Link here | |
46 | PillTracker, Ltd. | Right Patient • Right Pill • Right Time | We help Clinical trials run successfully by uniting HCP's and sponsors of innovative drugs together on one end-to-end platform to comply with FDA guidance to industry. PillTracker delivers critical, reliable med adherence and efficacy data to clinical trials so that caregivers can make timely decisions | Digital Health | Decision Support System, Medication Adherence, CRO, Telemedicine Solutions, Autoimmune Diseases, Neurology & Degenerative Disease | Oncology, Respiratory, | Initial Revenues | Series A | $2.3 Million | Yes, not disclosed | Not disclosed | $5M | 510K-Exempt | N/A | Providers, Payers (Insurance), Investors, Pharma, Health IT companies (EMRs), Hospitals, VC's | B2B, B2B2C | Yes. Offices in NY and DC. 2 employees in USA full-time. | Link here | Link here | |
47 | Plas-Free Ltd | Medical device to prevent excessive bleeding | Plas-Free Ltd, is a blood purification specialist focusing in critical care. By developing unique extracorporeal plasma adsorbents, Plas-Free is aiming to give better treatment for patients in emergency care | Medical Devices | Biomaterials & Plasma Products | Intensive Care, Internal Medicine | Clinical Trials | Seed | $3M | No | Asahi Kasei Medical | $5M | No | By 2023 | Investors, Pharma, Hospitals, VC's | B2B | N/A | Link here | Link here | |
48 | RADLogics | AI-software platform for automatic medical imaging analysis to improve accuracy and efficiency of radiologists | Founded in 2010, RADLogics is a healthcare software company that develops AI-Powered solutions that support image analysis to improve radiologists’ accuracy and productivity while enhancing patient outcomes. Based in New York, NY and Tel Aviv, Israel, we are one of the pioneers in using AI & machine learning image analysis and advanced big data analytics to search and analyze imaging data to help reduce diagnostics turnaround time from hours to minutes by automating detection and report generation functions. Our patented AI medical image analysis platform enables rapid development and deployment of AI algorithms, and provides seamless integration into existing and customized radiology workflows. | Digital Health | Artificial Intelligence, Decision Support System, Diagnostic, Imaging | Emergency Medicine, Inflammation, Oncology, Pulmonary | Revenue Growth | Series A | $9M | $2M | $NUAN, Einstein Hospital, Philadelphia | $7M | Yes | N/A | Providers, Investors, Hospitals, VC's | Saas, B2B | Delaware C-corp; 20 employees/consultants | Link here | Link here | |
49 | ResMetrix Medical | Remote monitoring system for Respiratory outpatients | Currently there is no effective way to monitor respiratory outpatients. Our system measures breathing patterns and volumetric changes of the lung using only a small, wearable patch, adhered to the body, that can be used with all ages. Remote monitoring of respiratory conditions can improve health outcomes and reduce emergency department visits, hospitalizations, length of hospital stays, and readmissions. Unlike existing devices, our remote monitoring patch can accurately detect mild, asymptomatic irregularities in breathing patterns and timely detect a major respiratory episode allowing for medical intervention and prevent ER visits and hospitalization. | Digital Health | Mobile Healthcare, Monitoring, Remote Monitoring, Wearables & IOT | Pulmonary, Respiratory | Seed | 1st | The Israeli Innovation Authority and the MindUP incubator in Israel | No | NA | $1M | No | N/A | Investors, Pharma, Hospitals, VC's, Rehabilitation Centers | Saas, B2B | not yet | Link here | Link here | |
50 | Respinova Ltd. | Breakthrough therapy for COPD | Respinova has developed a new device for the treatment of COPD. Respinova’s Pulsehaler™ technology is the first treatment to directly re-open the collapsed small airways of COPD patients, thereby reducing breathlessness and improving patient’s ability to walk. The technology was clinically proven in a clinical study, and published in the peer reviewed Journal of COPD. Our technology is protected by 6 patent families, with 16 issued patents and additional patents pending. | Medical Devices | Drug Delivery, Medical Equipment | Respiratory | Regulatory Approval | Series B | $7.5 million (including Horizon 2020 Grants | No | Communicare Health, Vincent Medical, Kaplan Medical Center, UCLA, Univ of Leuven | $10M | No | Approximately 6 months | Payers (Insurance), Investors, Pharma, VC's, Assisted Living Facilities | B2B, B2B2C, B2C | Planned for future | Link here | Link here | |
51 | Sanara Ventures | Sanara is a JV of Philips and Teva that invests in digital health and medical device technology | Sanara Ventures is a healthcare investment platform for innovative startups, comprising an Israeli Innovation Authority backed incubator, a devoted management team of highly skilled professionals and expertise that come with the leadership of global giants Philips Healthcare & Teva Pharmaceuticals. | Digital Health | Venture Capital | Ear, Nose and Throat (ENT), General Health, General Surgery, Genetic Disorders | N/A | N/A | $10M | N/A | Teva, Philips | $10M | We do not need | Soon | Investors, VC's, Other | other | yes | Link here | Link here | |
52 | Serenus.AI | AI-based platform for improved medical treatement decisions | Innovative startup, let by to physicians and machine learning specialists. Strong passion to improve patient outcomes by harnessing the power of AI/ML technologies. Developed AI-based platform to assist medical professionals and patients with their medical treatment decisions. Won international awards and grants. Active in Israel, UK and the US. | Digital Health | Artificial Intelligence, Decision Support System | Ear, Nose and Throat (ENT), Gastrointestinal, General Health, General Surgery | Initial Revenues | Seed | $3M | No | HealthTrio, NHS | $5M | We do not need | N/A | Providers, Payers (Insurance), Investors, VC's, Physicians/Physician's Groups | Saas, B2B, B2B2C | Yes, 2 employees | Link here | Link here | |
53 | Somatix | Somatix Remote Patient Monitoring - Data With A Purpose | Somatix is a provider of wearable-enabled Remote Patient Monitoring platform to healthcare providers. Our solution uses patented gesture detection technology and machine learning algorithms to analyze user’s gesture data in real-time, for generating insights on risk factors for adverse events, activity levels, sleep quality, poor medical compliance, falls, dehydration, irregularities, and more. This data delivers valuable clinical insights to healthcare providers, helping them improve the wellbeing of those under their care. | Digital Health | Artificial Intelligence, Decision Support System, Remote Monitoring, Wearables & IOT | Cardiovascular, General Health, Oncology, Rehabilitation | Initial Revenues | Series B | $13.2M, Digitalis Ventures, Forefront Analytics | Yes, not disclosed | Can provide in a meeting | $12M | We do not need | N/A | Providers, Hospitals, VC's, Rehabilitation Centers, Assisted Living Facilities, Large Tech Companies (Facebook, Google, Etc.) | Saas, B2B | Installed our system in NY, NJ, PA, CT and MN | Link here | Link here | |
54 | TanoMed Ltd. | Developing precise GI cancer immunotherapy by activating dendritic cells | Developing precise GI cancer immunotherapy by activating dendritic cells. Technology developed over the last six years in Tel Aviv University. Strong proof of concept in a range of cancer models including melanoma and CRC. Strong team and platform technology. | Nanotechnology - Biotechnology | Antibody, Immunotherapy & Vaccines, Drug Targeting, New Chemical Entity, Precision / Personalized Medicine | Gastrointestinal, Oncology | Seed | Seed | Pre-seed investment | No | N/A | $15M | No | About 4 years | Investors, Pharma | B2B2C | No | Link here | Link here | |
55 | Vaica | Remote Patient Monitoring Platform coupled with Medication Adherence IoT Devices | Vaica is a Telemedicine Company that offers an end-to-end Remote Patient Monitoring Platform (RPM) coupled with Smart Medication Adherence IoT Devices for increasing patient engagement, persistence and well-being. The ongoing global crisis of COVID-19 has put a spotlight on the need for RPM, as this service is well suited for chronic conditions and helps keep patients independent and safe at home. Vaica’s RPM solutions are reimbursable, adherence rates Meet top Star Rating by increasing medication adherence to 96% | Digital Health | Assistive Technologies, Disease Management, Medication Adherence, Remote Monitoring | General Health, Nephrology, Primary Care, Respiratory | Released | Series A | $5M | Yes, not disclosed | Merck, MUSC, CHOP, CCHMC, ECU, NCU, McGill University, Zabar Health, Sheba Tel Hashomer, HNP Italy, Biodeose Connect UK, Erlangen hospital Germany, Seattle children's hospital, Santa Helena Brazil, Healthcare at home Germany and more | To be disclosed upon request | We do not need | We are FDA exempt | Providers, Payers (Insurance), Investors, Pharma, Hospitals, Distributors, VC's, Rehabilitation Centers, Assisted Living Facilities, Other | Saas, B2B, Fee for service | Our president is located in SF, we are now shifting focus to grow our presence in the US | Link here | Link here | |
56 | WizeCare Technologies Ltd. | WizeCare's technology identifies, tracks and analyzes patient movement without the need of any sensors, wearables or depth cameras, seamlessly during the home PT session | WizeCare is a digital health company that has developed a unique solution for remote Physical therapy at the patients' homes. By today, WizeCare's solution has already crossed the 20,000 patient bar. It is clinically proven for CJR and Parkinson cases through 2 successful clinical studies showing better clinical outcomes and patients' adherence for home use compared to the conventional face-to-face physical therapy model. WizeCare's technology enables clinicians and healthcare providers to treat unlimited patients from afar and to bill Medicare and other insurers for the session, just like a face-to-face Physical therapy session in the facility. | Digital Health | Artificial Intelligence, Mobile Healthcare, Remote Monitoring, Telemedicine Solutions | Cardiovascular, General Health, Orthopedic, Rehabilitation | Initial Revenues | Series A | ~$2.5M - Spinach Angels, Rio VenturesHoldings | $0.5M | Cleveland Clinic, Meuhedet HMO, Clalit HMO | $3.5M | No | 6 months | Providers, Investors, Hospitals, Distributors, VC's, Rehabilitation Centers, Assisted Living Facilities | Saas, B2B, B2B2C | Hartford Connecticut, 3 employees | Link here | Link here | |
57 | XRHealth | XRHealth is the first VR Telehealth company in the world | XRHealth harnesses extended reality technology to improve patient health, reduce the cost of care, and empower clinicians to deliver improved outcomes. XRHealth is a medical provider, using its own proprietary technology to provide VR Telehealth services. Our Medical VR applications are FDA registered. We are using big data & data analytics to set the new gold standard for therapeutic care. We have a fully operational revenue cycle with Medicare and private payors in all our clinics around the world through the US, Australia and Israel. | Digital Health | AR/VR, Mobile Healthcare, Remote Monitoring, Telemedicine Solutions | Neurology & Degenerative Disease, Rehabilitation | Revenue Growth | Seed | $16.6M. Bridges Israel, Flint Capital. | $0.44M | MGH Boston, BIDMC Boston, Veterans Association USA, Bupa Australia, Sheba Hospital, Assaf Harofe, Soroka, Loewenstein Hospital | $20M | Yes | Approved. | Providers, Payers (Insurance), Investors, Hospitals, VC's, Rehabilitation Centers, Physicians/Physician's Groups | Saas, B2B, B2B2C | HQ in Boston, MA. 25 employees. | Link here | Link here | |
58 | Zebra Medical Vision | Transforming patient care with the power of AI | Zebra Medical Vision’s imaging analytics platform enables healthcare institutions to identify patients at risk of disease and offer improved, preventative treatment pathways, to bring better patient care. The company is funded by Khosla Ventures, Marc Benioff, Intermountain Investment Fund, OurCrowd Qure, Aurum, aMoon, Nvidia, J&J and Dolby Ventures. Zebra Medical Vision has raised $52 million in funding to date, and was named a Fast Company Top-5 AI and Machine Learning company. Zebra-Med leads the way in AI FDA cleared products, and is installed in hospitals globally, from Australia to India, Europe to the U.S, and the LATAM region. | Digital Health | Artificial Intelligence, Imaging | Bone Diseases, Cardiovascular, Oncology, Pulmonary | Released | D round in late 2021 | $52M- Khosla Ventures, aMoon. OurCrowd, J&J Ventures, Intermauntain Health Ventures | Yes, not disclosed | Philips, Canon, Intelerad, Change Healthcare, Nuance, J&J | $30-50M | Yes | Six month - 1 year, a part of the Digital Health Software Precertification (Pre-Cert) FDA Program | Payers (Insurance), Investors, Hospitals, Physicians/Physician's Groups | Saas, B2B | 2 Offices NYC and Dallas Texas, 7 employees | Link here | Link here | |
59 | ||||||||||||||||||||
60 | ||||||||||||||||||||
61 | ||||||||||||||||||||
62 | ||||||||||||||||||||
63 | ||||||||||||||||||||
64 | ||||||||||||||||||||
65 | ||||||||||||||||||||
66 | ||||||||||||||||||||
67 | ||||||||||||||||||||
68 | ||||||||||||||||||||
69 | ||||||||||||||||||||
70 | ||||||||||||||||||||
71 | ||||||||||||||||||||
72 | ||||||||||||||||||||
73 | ||||||||||||||||||||
74 | ||||||||||||||||||||
75 | ||||||||||||||||||||
76 | ||||||||||||||||||||
77 | ||||||||||||||||||||
78 | ||||||||||||||||||||
79 | ||||||||||||||||||||
80 | ||||||||||||||||||||
81 | ||||||||||||||||||||
82 | ||||||||||||||||||||
83 | ||||||||||||||||||||
84 | ||||||||||||||||||||
85 | ||||||||||||||||||||
86 | ||||||||||||||||||||
87 | ||||||||||||||||||||
88 | ||||||||||||||||||||
89 | ||||||||||||||||||||
90 | ||||||||||||||||||||
91 | ||||||||||||||||||||
92 | ||||||||||||||||||||
93 | ||||||||||||||||||||
94 | ||||||||||||||||||||
95 | ||||||||||||||||||||
96 | ||||||||||||||||||||
97 | ||||||||||||||||||||
98 | ||||||||||||||||||||
99 | ||||||||||||||||||||
100 |